Skip to main content
Signal8

ProMIS Neurosciences Inc. (PMN) Form 10-Q — Nov 12, 2026

$PMNForm 10-QFiled Nov 12, 2026, 4:19 PM ET0001104659-26-126263Original filing

ProMIS Neurosciences filed its Q3 2026 10-Q reporting a net loss of $8.2 million for the quarter and $28.1 million for the nine months ended September 30, 2026, with an accumulated deficit of $158.5 million and negative operating cash flow of $32.1 million for the nine months. The company said its January 2026 PIPE, which raised $70.1 million net, plus existing cash and short-term investments should fund operations through 2027, though it continues to warn it will need substantial additional funding and that financial statements were prepared on a going concern basis.

Key figures

Cash Position
existing cash and short-term investments expected to fund operations through 2027
Q3 net loss
8161868
Working capital
41800000
Precise ad sites
21
Q3 2025 net loss
11580126
Pmn310 q3 expense
5171867
Interim ariae rate
0% (no ARIA-E reported)
Interim ariah rate
4.4% (all mild and asymptomatic)
Shares outstanding
8996862
Accumulated deficit
158500000
Fully diluted shares
19334896
Plasma ptau217 decline
68.5% of patients showed declines from baseline; pooled ~15% decline
Csf mtbr tau243 decline
62.5% of patients showed declines; pooled ~13.3% decline
Nine month financing cash
70102381
Pmn310 nine month expense
19221406
Jan 2026 pipe net proceeds
70100000
Jan 2026 pipe gross proceeds
75500000
Precise ad enrolled subjects
144

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.